News & Press
by Rick Mullin
Contribution by Dr. Michael Quirmbach, Chief Executive Officer & President, CordenPharma
Chemical & Engineering News Magazine – April 27, 2020 / Volume 98, Issue 16
CordenPharma, a German CDMO that operates a network of plants in the US and Europe, is also managing well, according to CEO Michael Quirmbach. “We have a few disruptions in the supply chain, but not so severe. We have probably seen a little bit more, especially this week,” he told C&EN in early April.
CordenPharma, Quirmbach said, manufactures some of its own raw materials and precursor chemicals and procures some from its German sister company WeylChem—both are owned by the same investment firm, International Chemical Investors Group. “But for large-scale API, we are dependent on supply from China. Also from India,” Quirmbach acknowledged.
“There is increasing demand for certain lipids. And we are also looking at hydroxychloroquine because we used to manufacture it at our CordenPharmaBergamo site. But that was 10 to 15 years ago, and all of these things take some time to restart.”